바이젠셀&nbsp;주가가&nbsp;코스닥&nbsp;상장&nbsp;첫날 큰폭으로 하락하고&nbsp;있다.<br /> <br /> 25일&nbsp;오후&nbsp;1시57분&nbsp;기준&nbsp;바이젠셀&nbsp;주가는&nbsp;시초가보다&nbsp;17.69%(1만3천&nbsp;원)&nbsp;떨어진&nbsp;6만800원에&nbsp;거래되고&nbsp;있다.<br /> &nbsp; <figure class="image" style="float:right;margin-right:0px; margin-left:15px; margin-top:30px; "><img alt="바이젠셀 상장 첫날 주가 장중 급락, 공모가보다는 15% 높아" height="200" class='lazyload' data-src="https://www.businesspost.co.kr/news/photo/202108/20210825141724_22121.jpeg" width="300" /> <figcaption><table width=320><tr><td align='left' style='margin:0; padding:0px 0px; color:#306f7f; font-size:12px; font-family:verdana; letter-spacing:-0.1em; line-height:160%; table-layout: fixed; width:180px;'>▲ 바이젠셀 로고.</td></tr></table></figcaption> </figure> <br /> 공모가&nbsp;5만2700원보다는&nbsp;15.37%&nbsp;높은&nbsp;수준이다.<br /> <br /> 바이젠셀의&nbsp;시초가는&nbsp;공모보다&nbsp;약&nbsp;40%&nbsp;높은&nbsp;7만3500원으로&nbsp;형성됐다.<br /> <br /> 시초가는&nbsp;상장일&nbsp;오전&nbsp;8시30분부터&nbsp;9시 사이에&nbsp;공모가의&nbsp;90%~200%&nbsp;수준에서&nbsp;호가를&nbsp;접수해&nbsp;매도호가와&nbsp;매수호가가&nbsp;만나는 가격으로&nbsp;정해진다.<br /> <br /> 바이젠셀은&nbsp;12~13일&nbsp;진행한&nbsp;일반투자자&nbsp;청약에서&nbsp;886.2대1의&nbsp;경쟁률을&nbsp;보였다.&nbsp;증거금은&nbsp;11조131억&nbsp;원이&nbsp;몰렸다.<br /> <br /> 기관투자자&nbsp;대상&nbsp;수요예측에서는&nbsp;1271대1의&nbsp;경쟁률을&nbsp;보였다.&nbsp;이에&nbsp;공모가는&nbsp;희망범위&nbsp;4만2800원~5만2700원의&nbsp;최상단에서&nbsp; 결정됐다.<br /> <br /> 바이젠셀은&nbsp;신약&nbsp;연구개발&nbsp;및&nbsp;면역세포치료제의&nbsp;개발과&nbsp;제조&nbsp;등&nbsp;사업을&nbsp;하는&nbsp;바이오벤처회사인데 2013년&nbsp;2월 설립됐다. [비즈니스포스트&nbsp;박안나&nbsp;기자]